Heparin and Bivalirudin in Percutaneous Coronary Intervention for Acute Coronary Syndromes
Author Information
Author(s): Guiping Wang, Kaijie Qi, Li Xuyang, Zuo Shuping, Zhang Ruolin, Zhao Yanan, Sun Suya, Zhang Juanjuan, Liu Xiaokun
Primary Institution: Tangshan Gongren Hospital, Tangshan, Hebei Province, China
Hypothesis
What are the differences in efficacy and safety between heparin and bivalirudin as anticoagulants during percutaneous coronary intervention for acute coronary syndromes?
Conclusion
Bivalirudin-based anticoagulation regimens may reduce bleeding risk compared to heparin, but do not show a clear advantage in preventing myocardial infarction or stent thrombosis.
Supporting Evidence
- Bivalirudin significantly reduced major bleeding compared to heparin in several trials.
- Patients treated with bivalirudin showed a higher incidence of in-stent thrombosis.
- The HORIZONS-AMI trial indicated that bivalirudin reduced clinical adverse events compared to heparin plus GPI.
- The EUROMAX study found bivalirudin reduced the risk of the primary outcome compared to heparin.
- The MATRIX trial showed no significant difference in major adverse cardiovascular events between bivalirudin and heparin.
Takeaway
This study looks at two blood thinners used during heart procedures and finds that one may cause less bleeding, but both work similarly in preventing heart problems.
Methodology
A literature review of randomized controlled trials comparing heparin and bivalirudin in patients undergoing PCI for ACS.
Limitations
The applicability of some trial results may be limited due to changes in clinical practice since their publication.
Participant Demographics
The studies included a diverse population of patients with acute coronary syndromes, including STEMI and NSTEMI.
Statistical Information
P-Value
p = 0.005
Confidence Interval
95% CI 0.63–0.92
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website